What Is the Lowest Dose of Amiodarone?

The most commonly prescribed lowest maintenance dose of amiodarone is 200 mg taken once daily, and many guidelines describe this as the floor for long-term rhythm control. In practice, though, some patients are maintained on 100 mg per day or even as little as 50 mg per day. The answer depends on why the drug was prescribed, how the patient responds, and what side effects emerge over time. Amiodarone’s unusual body chemistry makes “lowest dose” a more complicated question than it first appears.

What Qualifies as Low Dose

Amiodarone dosing typically moves through two phases. The loading phase, which can run from days to weeks, uses high daily doses (often 400 to 800 mg per day, sometimes more in a hospital setting) to saturate the body’s fat and organ tissues. Once the drug reaches a therapeutic level, the dose drops to a maintenance level intended to keep arrhythmias under control while reducing side-effect risk. For most people, maintenance lands at 200 mg per day. A review of optimal management concluded that 200 mg per day maintains arrhythmia control and minimizes side effects in many patients after the initial loading period.¹

A systematic review and meta-analysis defined low-dose amiodarone as 200 mg per day or less, and very-low-dose as 100 mg per day or less. At 200 mg per day, roughly 17% of patients experienced some side effect, and about 6% needed to stop the drug. At 100 mg per day, those numbers dropped: about 11% had any side effect, and only about 2% had to discontinue.² Those figures suggest a meaningful safety advantage to going below 200 mg, though the tradeoff is always whether the arrhythmia stays controlled.

At the extreme end, a study of patients with persistent atrial fibrillation examined whether 50 mg per day could help maintain normal rhythm. The researchers found that even this very small dose may contribute to keeping the heart in a normal rhythm in carefully selected patients, although half of those studied still needed an electrical cardioversion to restore their rhythm in the first place.³ So 50 mg per day is not a standard starting point, but it exists in clinical use for people who either respond unusually well or cannot tolerate higher doses.

Why Such a Small Amount Can Still Work

Amiodarone is unlike most heart medications in how the body handles it. The drug is extremely fat-soluble, meaning it accumulates in fatty tissues, the liver, lungs, skin, and other organs over weeks and months. Once those tissues are saturated, even a small daily dose is enough to keep blood levels in a therapeutic range because the drug is being slowly released from its tissue stores. Population-level studies of amiodarone’s behavior in the body confirm that the drug has an extraordinarily long elimination half-life, which makes timing dose adjustments to avoid toxicity “unusually perplexing.”⁴ Depending on how long someone has been taking it, the effective half-life can stretch to 40 to 55 days or even longer.

The drug also has an active breakdown product called desethylamiodarone. This metabolite builds up gradually and has its own significant effects on heart electrical activity, including slowing conduction and extending how long heart tissue takes to “reset” between beats.⁵ Animal and clinical research has shown that both amiodarone and desethylamiodarone lengthen the electrical cycle of heart cells, and the metabolite may account for a large part of the drug’s delayed therapeutic and toxic effects.⁶ This is why lowering the daily dose does not produce an immediate change in the drug’s effects: the tissue stores and the metabolite keep working for weeks after any adjustment.

One practical consequence is that oral amiodarone raises the defibrillation threshold over time, meaning implantable defibrillators may need more energy to shock the heart back into rhythm. Research suggests this effect is largely driven by desethylamiodarone rather than the parent drug, since intravenous amiodarone, given before the metabolite accumulates, does not seem to raise the threshold the same way.⁷ For patients with implantable devices, this is worth knowing: even a low oral dose, taken long enough, can change how their device performs.

How Low-Dose Amiodarone Performs for Atrial Fibrillation

Atrial fibrillation is the most common reason amiodarone is prescribed long term. A study that followed 49 patients over an average of nearly two years found that 82% had their atrial fibrillation controlled on amiodarone. The weekly doses required varied widely. About a fifth of patients did well on less than 300 mg per week, which works out to roughly 40 mg per day. Another 35% were controlled on 301 to 500 mg per week, while 20% needed 701 to 1,000 mg per week.⁸ The takeaway is that there is no single lowest effective dose that applies to everyone. Some people maintain control on amounts well below the textbook 200 mg per day, while others need more.

Part of this variation comes from the drug’s tissue accumulation. A patient who has been on a standard dose for years and then tapers down is carrying a large reservoir of the drug in their body. For that person, a small maintenance dose is topping off an already full tank. A lighter or leaner person, or someone who started at a lower dose from the outset, will have less stored drug and may need more to stay in rhythm. There is no reliable formula for predicting who will do well at which dose, which is why clinicians often rely on trial-and-error tapering paired with regular monitoring.

Preventing Arrhythmias After Heart Surgery

A distinct use for low-dose amiodarone is preventing atrial fibrillation that develops after cardiac surgery, a complication that affects roughly a quarter to a third of patients who undergo bypass grafting. Two recent studies tested whether a short course of low-dose amiodarone given before and after off-pump coronary bypass surgery could reduce this risk. One trial found that low-dose amiodarone prophylaxis cut the rate of new atrial fibrillation requiring treatment by about 11 percentage points, with no apparent adverse effects from the drug.⁹ A separate randomized trial reported that the rate of post-operative atrial fibrillation was 16% in the amiodarone group compared with 33% in the placebo group.¹⁰

In these surgical settings, the drug is used for days to weeks rather than months, and the doses are below what would be used for long-term rhythm control. Because the course is short, the deep tissue accumulation that drives long-term side effects has less time to develop. This is one of the clearest examples of low-dose amiodarone providing a measurable benefit with a relatively limited safety burden.

Side Effects Do Not Disappear at Low Doses

One of the most important things to understand about amiodarone is that lowering the dose reduces but does not eliminate the risk of serious organ toxicity. The drug can damage the lungs, thyroid, liver, eyes, and skin, and these problems have all been documented at 200 mg per day or less.

Lungs

Lung toxicity is the most feared complication because it can be fatal. Patients taking 400 mg or more per day have been reported to develop pulmonary toxicity at rates between 5% and 20%.¹¹ Lower doses bring lower rates, but they do not bring zero. A study focused specifically on patients receiving 200 mg per day concluded that pulmonary toxicity can occur at this dose and that clinicians must remain alert even with low-dose therapy.¹² In a real-world Korean registry where the average dose was about 227 mg per day, lung toxicity appeared in about 0.3% of patients.¹³ That is a small percentage, but given the seriousness of the complication, it warrants ongoing surveillance with chest imaging and pulmonary function assessments.

Thyroid

Each 200-mg tablet of amiodarone contains about 75 mg of iodine, and the body absorbs a substantial fraction of it. This iodine load is many times what a person would get from their diet, and it can push the thyroid toward underactivity or, less commonly, overactivity.¹⁴ In the Korean registry, thyroid problems occurred in about 2.5% of patients on low-dose treatment.¹³ A study of adults with congenital heart disease found a much higher rate of thyroid dysfunction, 36%, with female sex and complex cyanotic heart disease as significant risk factors. In that population, taking more than 200 mg per day also appeared to raise the odds of thyroid trouble.¹⁵ The wide difference between 2.5% and 36% reflects how much the underlying patient population matters. Most clinicians check thyroid function every few months for anyone on amiodarone, regardless of dose.

Liver

Liver injury from amiodarone tends to be slow and insidious. A case report documented full liver cirrhosis in a patient who took 200 mg per day for 84 months. The damage was found at autopsy; during life, the only signs were mildly elevated liver enzymes and an enlarged liver. The authors emphasized that long-term use of even low doses carries the risk of irreversible liver injury and that periodic liver function testing or biopsy may be necessary.¹⁶ In the Korean registry, liver toxicity occurred in about 2.2% of patients.¹³

Eyes and Skin

Corneal microdeposits develop in virtually all patients who take amiodarone for more than six months. These tiny deposits form because the drug is secreted into tears and then absorbed by the cornea. About 10% of people with these deposits notice visual symptoms like glare or halos around lights, though the problem is usually not severe enough on its own to stop the medication.¹⁷ Skin side effects, particularly a blue-gray discoloration on sun-exposed areas, are also tied to the total amount of drug accumulated over time rather than the daily dose alone. Using sunscreen and limiting sun exposure helps, but the discoloration can take years to fade after the drug is stopped.

Duration Matters More Than You Might Expect

A finding from the Korean registry worth highlighting is that the only independent predictor of adverse effects was the duration of amiodarone treatment, not the daily dose. Each additional year on the drug increased the odds of side effects by about 21%.¹³ This makes sense given how the drug piles up in tissues over time. A patient on 100 mg per day for five years may carry as much total drug burden as someone who took 200 mg per day for a shorter stretch. The cumulative load, not just the daily number on the pill bottle, is what drives many of the organ-level complications.

This is a useful corrective to the assumption that “lower dose equals safe.” A low daily dose taken indefinitely is not inherently low risk. Regular monitoring of thyroid, liver, lung, and eye health remains important for the entire duration of treatment, and the conversations around whether to continue amiodarone should happen periodically, weighing the ongoing benefit against the rising cumulative exposure.

Drug Interactions Persist at Any Dose

Amiodarone interferes with several liver enzymes that break down other medications, and these interactions do not go away at lower doses. The most clinically important interaction is with warfarin, a common blood thinner. Research in humans showed that amiodarone decreases the body’s ability to clear warfarin by inhibiting a specific liver enzyme responsible for processing the active form of the drug.¹⁸ The practical result is that warfarin’s blood-thinning effect gets amplified, raising the risk of bleeding. Patients starting amiodarone alongside warfarin typically need their warfarin dose cut by a third to a half, with frequent blood testing until a new stable level is found.

Amiodarone also interacts with digoxin, certain statins, and other heart rhythm drugs. Because amiodarone and its metabolite linger in the body for weeks after discontinuation, these interactions persist long after the last amiodarone tablet. Switching to a lower amiodarone dose does not meaningfully reduce the strength of these interactions, because the enzyme inhibition is already occurring at low tissue concentrations. Any patient on amiodarone, at any dose, needs their other medications reviewed carefully.

Intermittent and Alternate-Day Dosing

Because of amiodarone’s extremely long half-life, some clinicians prescribe the drug on an intermittent schedule rather than daily. A common approach is to take 200 mg five days a week with two days off, or 200 mg every other day. The study of 49 atrial fibrillation patients mentioned earlier found success at a range of weekly doses, with a fifth of patients controlled on less than 300 mg per week, equivalent to a 200-mg tablet taken roughly every five days.⁸

Alternate-day or intermittent dosing is appealing because it reduces total weekly exposure, which in theory should slow tissue accumulation and lower side-effect risk. The meta-analysis data showing better tolerability at 100 mg per day compared with 200 mg per day supports this logic indirectly: less drug in, fewer problems out.² The challenge is that there are no large randomized trials specifically comparing fixed daily dosing against intermittent schedules at matched weekly totals. Most of the evidence comes from observational data and clinical experience. If your doctor suggests skipping days, it is a reasonable strategy grounded in the drug’s pharmacology, even if it has not been tested with the same rigor as fixed daily doses.

How Low-Dose and High-Dose Infusions Compare in Acute Settings

The discussion so far has focused on oral tablets for long-term use, but amiodarone is also given intravenously in hospital settings to convert acute atrial fibrillation or flutter back to normal rhythm. A randomized trial compared a high-dose infusion protocol (900 mg over 30 minutes followed by 1,200 mg over 24 hours) against a low-dose protocol (300 mg over 30 minutes followed by 900 mg over 24 hours). At 24 hours, 90% of the high-dose group and 80% of the low-dose group had converted to normal rhythm or achieved a controlled heart rate, a difference that was not statistically significant. However, symptomatic low blood pressure occurred in 37% of the high-dose group compared with 10% of the low-dose group, a statistically significant gap.¹⁹ These IV doses are much higher than oral maintenance doses and are used for hours to days rather than months, but the study reinforces a pattern: lower amiodarone doses often achieve similar rhythm-control results with fewer immediate complications.

What Stopping Amiodarone Actually Looks Like

Because of the massive tissue stores, stopping amiodarone is not like stopping most medications. Even after the last pill, the drug and its metabolite continue to circulate for weeks to months. This means that side effects discovered during treatment will not resolve quickly after discontinuation, and drug interactions remain relevant for a prolonged period. Clinicians sometimes taper the dose before stopping entirely, both to watch for arrhythmia recurrence at each step and to allow the body to begin clearing its stored drug. There is no standardized tapering protocol; the approach is individualized based on the reason the drug was started, how long the patient has been on it, and what alternatives are available.

For patients who have been on amiodarone for years, the slow washout period can stretch past three months. Thyroid function and liver enzymes should continue to be monitored during this time. If a patient switches to a different rhythm-control drug, the overlap period requires special attention because amiodarone’s lingering effects can amplify or conflict with the new medication. The drug’s uniquely long shadow is one more reason why the question of “lowest dose” carries weight: every milligram you can safely avoid adds up over the months and years it takes the body to fully clear what has already accumulated.

1
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Optimal Management of Amiodarone Therapy: Efficacy and Side Effects
2
The Journal of Innovations in Cardiac Rhythm Management. Low-dose Amiodarone Is Safe: A Systematic Review and Meta-analysis
3
PubMed Central. Long‐Term Safety of Extremely Low‐Dose Amiodarone at 50 mg Daily in Patients With Persistent Atrial Fibrillation
4
PubMed. Population pharmacokinetics of long-term oral amiodarone therapy
5
PubMed. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite
6
PubMed. Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose and drug concentrations to intracellular inclusion bodies
7
Journal of the American College of Cardiology. Effects of Amiodarone and Its Active Metabolite Desethylamiodarone on the Ventricular Defibrillation Threshold
8
Journal of Cardiac Failure. Low Dose Amiodarone for Atrial Fibrillation
9
Heart & Lung. Amiodarone Prophylaxis against postoperative atrial fibrillation in off-pump coronary artery bypass
10
The Cardiothoracic Surgeon. Does prophylactic low-dose amiodarone decrease the incidence of postoperative atrial fibrillation after coronary artery bypass graft surgery? A randomized controlled trial
11
International Journal of Cardiology. Low dose amiodarone-induced lung injury
12
PubMed. Pulmonary toxicity in patients receiving low-dose amiodarone
13
PubMed Central. The incidence and predictors of overall adverse effects caused by low dose amiodarone in real-world clinical practice
14
PubMed Central. Management of amiodarone-related thyroid problems
15
PubMed. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease
16
PubMed Central. Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report
17
PubMed Central. Acute onset of halos and glare: bilateral corneal epithelial edema with cystic eruptions–atypical presentation of amiodarone keratopathy
18
PubMed. The mechanism of the interaction between amiodarone and warfarin in humans
19
PubMed Central. Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment